Evidence map›Paper›PMID 36405311›Full record

ArticleFrontiers in chemistry2022

Precise dapagliflozin delivery by cardiac homing peptide functionalized mesoporous silica nanocarries for heart failure repair after myocardial infarction.

Lijiao You, Qing Wang, Yuhui Ma, Yunfeng Li, Hui Ye, Lingli Xu, Ming Lei

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lijiao YouDepartment of Critical Care Medicine, Seventh People's Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Qing WangDepartment of Critical Care Medicine, Seventh People's Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Yuhui MaDepartment of Critical Care Medicine, Seventh People's Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Yunfeng LiDepartment of Critical Care Medicine, Seventh People's Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Hui YeDepartment of Critical Care Medicine, Seventh People's Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Lingli XuDepartment of Critical Care Medicine, Seventh People's Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Ming LeiDepartment of Critical Care Medicine, Seventh People's Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Shanghai University of Traditional Chinese Medicine · CNSeventh People's Hospital of Shanghai · CNShanghai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial infarction (MI) may cause irreversible damage or destroy to part of the heart muscle, affecting the heart's ability and power to pump blood as efficiently as before, often resulting in heart failure (HF). Cardiomyocyte death and scar formation after MI may then trigger chronic neurohormonal activation and ventricular remodeling. We developed a biocompatible and mono-dispersed mesoporous silica nanoparticles (MSN) divergent porous channel for dapagliflozin (DAPA) loading. After surface modification of the cardiac-targeting peptides, the novel drug delivery system was successfully homed, and precisely released drugs for the hypoxic and weak acid damaged cardiomyocytes. Our biocompatible MSN- based nanocarriers for dapagliflozin delivery system could effective cardiac repair and regeneration

Indexed as

dapagliflozinheart failure repairhypoxia-inducible factor 1-α (HIF-1α)myocardial infarctionnano-targeted drugs delivery system

Identifiers

PMID36405311
PMCPMC9671955
OpenAlexW4308071402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.